February 10, 2014
Westlake, OH. February 10, 2014 – GenomOncology and Vanderbilt-Ingram Cancer Center (VICC) today announced a partnership for the exclusive commercial development of a decision support tool based on My Cancer Genome™, an online precision cancer medicine knowledge resource for physicians, patients, caregivers and researchers.
Through this collaboration, GenomOncology and VICC will enhance My Cancer Genome through the development of a new genomics content management tool. The MyCancerGenome.org website will remain free and open to the public. In addition, GenomOncology will develop a decision support tool based on My Cancer Genome™ data that will enable automated interpretation of mutations in the genome of a patient’s tumor, providing actionable results in hours versus days. According to the terms of the agreement, all commercial use of My Cancer Genome™ in any form will be licensed through GenomOncology.
Vanderbilt-Ingram Cancer Center (VICC) launched My Cancer Genome™ in January 2011 as an integral part of their Personalized Cancer Medicine Initiative that helps physicians and researchers track the latest developments in precision cancer medicine and connect with clinical research trials. This web-based information tool is designed to quickly educate clinicians on the rapidly expanding list of genetic mutations that impact cancers and enable the research of treatment options based on specific mutations. For more information on My Cancer Genome™ visitwww.mycancergenome.org/about/what-is-my-cancer-genome.
“The future of cancer diagnostics and treatment is genomics-based precision medicine. Therapies based on the specific genetic alterations that underlie a patient’s cancer not only result in better outcomes but often have less adverse reactions,” commented Manuel Glynias, President and CEO of GenomOncology. “A resource like My Cancer Genome™ that matches tumor mutations to therapies and makes information accessible and convenient is an incredibly valuable tool. Our collaboration with Vanderbilt-Ingram Cancer Center on My Cancer Genome™ is designed to keep this resource comprehensive, scalable and easy for clinicians to use.”
“We are excited about the opportunity to collaborate with GenomOncology to enhance My Cancer Genome™ and develop tools for other hospitals, labs and cancer centers to use for patient care,” said Mia Levy M.D., Ph.D., co-founder of the My Cancer Genome™ site. “We believe in the need for high-quality, curated information to educate physicians and give them confidence as they make treatment decisions for patients.”
About Vanderbilt-Ingram Cancer Center
Vanderbilt-Ingram Cancer Center, a National Cancer Institute–designated Comprehensive Cancer Center, conducts basic, translational, and clinical research that offers adult and pediatric oncology treatment. VICC is a member of the National Comprehensive Cancer Network along with 22 other leading centers working together to improve quality and effectiveness of cancer care. For more information about VICC and precision medicine visit www.vicc.org.
GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed the GO Clinical Workbench™, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient’s tumor genome into an actionable clinical report. GenomOncology’s research platform, GenomAnalytics™, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries about the biology of cancer. More information can be found on the company’s website at www.genomoncology.com.
For more information regarding this announcement, please contact:
Jane Krug, PR Contact